News | February 16, 2022
Mankind Pharma acquires two brands from Dr Reddy’s
The entire integration and transition of the brands is expected to be completed by March 2022
The entire integration and transition of the brands is expected to be completed by March 2022
Key takeaways of Q3FY22 quarter & conference call highlights
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
The company will donate 5000 nebulizers to primary health care centres in rural India
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
